athenex-logo_750xx739-416-0-70.jpg
Athenex 宣佈為 Tirbanibulin 提供額外的許可協議
July 26, 2021 07:00 ET | Athenex, Inc.
紐約水牛城, July 26, 2021 (GLOBE NEWSWIRE) -- 全球生物製藥公司 Athenex, Inc., (NASDAQ: ATNX) 是一家致力於發現、開發和商業化治療癌症和相關疾病的新療法。該公司今天宣佈已與 CSL Limited 的子公司 Seqirus Pty Ltd (「Seqirus」) 及用於 tirbanibulin 的 AVIR Pharma...
athenex-logo_750xx739-416-0-70.jpg
Athenex Announces Additional Licensing Agreements for Tirbanibulin
July 26, 2021 07:00 ET | Athenex, Inc.
BUFFALO, N.Y., July 26, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies...
athenex-logo_750xx739-416-0-70.jpg
Athenex 將在 2021 年 8 月 5 日為 2021 年第二季度提供企業及財務更新
July 23, 2021 04:26 ET | Athenex, Inc.
紐約水牛城, July 23, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX) 是一家致力於研究與開發用於治療癌症和相關疾病的新療法,並將其商業化的全球生物製藥公司。今天宣佈將在 2021 年 8 月 5 日(星期四)的市場開放前,發表 2021 年第二季度的企業及財務更新。Athenex 的管理團隊將於上午...
athenex-logo_750xx739-416-0-70.jpg
Athenex to Provide Corporate and Financial Update for the Second Quarter 2021 on August 5, 2021
July 22, 2021 08:47 ET | Athenex, Inc.
BUFFALO, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies...
athenex-logo_750xx739-416-0-70.jpg
Athenex 宣佈歐盟委員會批准 Klisyri® (tirbanibulin) 用於光化性角化病的局部治療
July 20, 2021 10:55 ET | Athenex, Inc.
紐約水牛城, July 20, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) 作為一家致力發現、開發和商業化癌症及相關疾病新治療的全球生物製藥公司,今天宣佈其合作夥伴 Almirall (Almirall, S.A., BME: ALM) 已從歐盟委員會獲得 Klisyri® (tirbanibulin)...
athenex-logo_750xx739-416-0-70.jpg
Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis
July 19, 2021 10:51 ET | Athenex, Inc.
BUFFALO, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies...
athenex-logo_750xx739-416-0-70.jpg
Athenex 提供與 FDA 進行關於口服紫杉醇加 Encequidar 用於治療轉移性乳癌的 A 型會議更新資訊
July 06, 2021 07:00 ET | Athenex, Inc.
美國紐約水牛城, July 06, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) 作為一家致力發現、開發和商業化治療癌症和相關疾病新療法的全球生物製藥公司,今天宣佈公司剛在 2021 年第二季與美國食品藥品管理局 (FDA) 進行 A 型會議,以討論在 2 月收到的完整回覆函所提出的不足之處。 在會議上,Athenex...
athenex-logo_750xx739-416-0-70.jpg
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer
July 06, 2021 07:00 ET | Athenex, Inc.
BUFFALO, N.Y., July 06, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies...
athenex-logo_750xx739-416-0-70.jpg
Athenex 在 ASCO2021 虛擬科學項目上展示了口服多西紫杉醇和口服紫杉醇的數據
June 04, 2021 10:18 ET | Athenex, Inc.
口服多西紫杉醇第 I 期藥代動力學研究數據表明,口服給藥可達到與靜脈注射多西紫杉醇相當的暴露劑量基於口服紫杉醇第 III 期研究中更新的腫瘤亞型的事後亞組療效分析證明,口服紫杉醇加 encequidar 可提高腫瘤亞組的反應率 紐約水牛城, June 04, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX)...
athenex-logo_750xx739-416-0-70.jpg
Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program
June 04, 2021 09:05 ET | Athenex, Inc.
Data from oral docetaxel phase I pharmacokinetic study shows oral administration can achieve exposure comparable to IV docetaxelPost-hoc subgroup efficacy analysis based on updated tumor subtypes in...